Exhibit D

JOINT FILING AGREEMENT

     The undersigned hereby agree that the Statement on Schedule 13D, dated August 9, 2010, as amended by Amendment No. 1 to Schedule 13D originally filed on October 4, 2010 (the “Schedule 13D”), and the Amendment No. 2 to the Schedule 13D, dated October 22, 2010 (the “Amendment No. 2”), (including any subsequent amendments, restatements, supplements, and/or exhibits thereto) with respect to the common shares, without par value, of Response Biomedical Corp. was and is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Amendment No. 2. Each of the undersigned agrees to be responsible for the timely filing of the Amendment No. 2, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 22nd day of October, 2010.

Dated: October 22, 2010	ORBIMED ADVISORS LLC
	a Delaware Limited Liability Company
	By:	/s/ Samuel D. Isaly Samuel D. Isaly
		Managing Member
	ORBIMED ADVISORS LIMITED
	a Cayman Islands corporation
	By:	/s/ Samuel D. Isaly Samuel D. Isaly
		Director
	ORBIMED ASIA GP, L.P.
	a Cayman Islands limited partnership
	By: ORBIMED ADVISORS LIMITED, its general partner
	By:	/s/ Samuel D. Isaly Samuel D. Isaly
		Director
	ORBIMED CAPITAL GP III LLC
	a Delaware limited liability company
	By: ORBIMED ADVISORS LLC, its managing member
	By:	/s/ Samuel D. Isaly Samuel D. Isaly
		Managing Member
	SAMUEL D. ISALY
	By:	/s/ Samuel D. Isaly Samuel D. Isaly

11